Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021
The Pharma Data
JULY 12, 2021
These data include results from a late-breaking presentation from a Phase 2a study evaluating the safety and pharmacokinetics (PK) of once-monthly (QM) oral islatravir for pre-exposure prophylaxis (PrEP) through 24 weeks. Safety and Pharmacokinetics of Islatravir in Study Participants with Severe Renal Insufficiency. Abstract 2361.
Let's personalize your content